A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA A -α5...
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA A -α5 NAM (basmisanil) on intellectual disability associated with Down syndrome
About this item
Full title
Author / Creator
Goeldner, Celia , Kishnani, Priya S , Skotko, Brian G , Casero, Julian Lirio , Hipp, Joerg F , Derks, Michael , Hernandez, Maria-Clemencia , Khwaja, Omar , Lennon-Chrimes, Sian , Noeldeke, Jana , Pellicer, Sabine , Squassante, Lisa , Visootsak, Jeannie , Wandel, Christoph , Fontoura, Paulo , d'Ardhuy, Xavier Liogier and Clematis Study Group
Publisher
England
Journal title
Language
English
Formats
Publication information
Publisher
England
More information
Scope and Contents
Contents
There are currently no pharmacological therapies to address the intellectual disability associated with Down syndrome. Excitatory/inhibitory imbalance has been hypothesized to contribute to impairments in cognitive functioning in Down syndrome. Negative modulation of the GABA
-α5 receptor is proposed as a mechanism to attenuate GABAergic functio...
Alternative Titles
Full title
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA A -α5 NAM (basmisanil) on intellectual disability associated with Down syndrome
Authors, Artists and Contributors
Author / Creator
Kishnani, Priya S
Skotko, Brian G
Casero, Julian Lirio
Hipp, Joerg F
Derks, Michael
Hernandez, Maria-Clemencia
Khwaja, Omar
Lennon-Chrimes, Sian
Noeldeke, Jana
Pellicer, Sabine
Squassante, Lisa
Visootsak, Jeannie
Wandel, Christoph
Fontoura, Paulo
d'Ardhuy, Xavier Liogier
Clematis Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_35123401
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_35123401
Other Identifiers
E-ISSN
1866-1955
DOI
10.1186/s11689-022-09418-0
